Company Overview

EVIO, Inc. is a life sciences and analytical testing company that historically focused on the regulated cannabis industry through laboratory testing, quality assurance, and compliance services. The company operated in sectors tied to cannabis product safety, agricultural testing, and scientific analytics, with business activities centered on helping cultivators, processors, dispensaries, and product manufacturers meet state regulatory requirements. Public disclosures and prior filings indicate that EVIO’s revenue drivers were primarily laboratory testing services, consulting, and licensing arrangements associated with cannabis quality control infrastructure.

The company evolved from a broader biotechnology and diagnostics focus into cannabis testing and compliance services as U.S. state-level cannabis legalization expanded. EVIO pursued a strategy of building a network of accredited laboratories and affiliated operations in regulated markets. Available public information indicates the company experienced operational and financial restructuring over time, and some historical business activities, market positioning, and operational scale are difficult to verify consistently across recent filings and market disclosures. Data inconclusive based on available public sources regarding the company’s current operating scale and active laboratory footprint.

Business Operations

EVIO’s operations historically centered on analytical testing and compliance services performed through its laboratory network and affiliated entities. Its activities included potency testing, pesticide screening, microbiological analysis, residual solvent testing, and product validation for cannabis-related products. The company also promoted consulting and advisory capabilities tied to laboratory accreditation, quality systems, and regulatory compliance. Public filings and corporate communications referenced operations in multiple U.S. states through owned, managed, licensed, or affiliated laboratories.

The company’s business model relied on a combination of direct testing revenue, licensing arrangements, and strategic laboratory partnerships. EVIO previously referenced relationships with independent laboratory operators and regional cannabis businesses to expand market reach without fully building company-owned infrastructure in every jurisdiction. Historical disclosures also referenced intellectual property, laboratory methodologies, and compliance-oriented service offerings as strategic assets. However, the status of certain partnerships, subsidiaries, and operational facilities has varied across reporting periods, and some details cannot be fully confirmed from current public information.

Strategic Position & Investments

EVIO’s strategic direction historically emphasized positioning itself as a standardized compliance and testing platform within the fragmented U.S. cannabis industry. The company sought growth through acquisitions, laboratory affiliations, and state-by-state expansion into regulated cannabis markets. Public disclosures referenced efforts to establish nationally recognized testing standards and create scalable laboratory operations capable of serving multiple legalized jurisdictions. The company also explored opportunities tied to hemp-derived products and broader agricultural analytics as regulatory frameworks evolved.

The company announced or pursued investments and acquisitions involving regional cannabis testing laboratories and operational partnerships intended to strengthen market coverage. Historical references included expansion initiatives in states such as Oregon, California, Colorado, and Florida. EVIO’s strategic narrative consistently emphasized regulatory compliance, product safety, and laboratory accreditation as differentiators in an industry with increasing oversight requirements. Publicly available information does not conclusively establish the present operational status of all previously announced subsidiaries, investments, or expansion initiatives.

Geographic Footprint

EVIO, Inc. was headquartered in the United States, with historical operations and affiliations concentrated in regulated U.S. cannabis markets. Public disclosures identified activity or planned activity in states including Oregon, California, Colorado, Florida, and additional emerging cannabis jurisdictions. The company’s market presence was primarily domestic, reflecting the regulatory structure of the U.S. cannabis industry, where state-level licensing frameworks strongly influence laboratory operations.

The company’s geographic strategy focused on entering jurisdictions with expanding medical or adult-use cannabis programs. EVIO did not maintain a widely disclosed multinational operating footprint comparable to larger global life sciences firms, although it positioned itself within an industry with growing international relevance. Available public information does not confirm substantial operational influence outside the United States.

Leadership & Governance

EVIO, Inc. has undergone multiple leadership and governance changes over time, consistent with restructuring activity and shifts in strategic direction. Historical public filings identified executives with backgrounds in biotechnology, laboratory sciences, cannabis regulation, and corporate development. The company’s leadership approach emphasized regulatory compliance, scientific credibility, and expansion through partnerships and acquisitions within emerging cannabis markets.

Key executives and leadership figures identified in public disclosures have included:

• William Waldrop – Chief Executive Officer
• Melanie J. Wolk – Former Chief Executive Officer
• Lori Glauser – Former Chief Financial Officer
• David LaNeve – Former executive leadership role associated with strategic development

Public disclosures indicate that leadership frequently emphasized building standardized testing infrastructure and supporting regulatory transparency in the cannabis industry. Due to changes in management over multiple reporting periods, some executive roles and governance structures may no longer reflect the company’s current organization.